内镜逆行胰胆管造影术后胰腺炎的发病机制及药物预防研究

被引:8
作者
孙勇 [1 ]
贾红 [2 ]
机构
[1] 四川省泸州医学院附属医院消化内科
[2] 四川省泸州医学院公共卫生系
关键词
胰腺炎; ERCP后胰腺炎; 发病机制; 药物预防;
D O I
暂无
中图分类号
R576 [胰腺疾病];
学科分类号
100201 [内科学];
摘要
内镜逆行胰胆管造影术(ERCP)是广泛用于肝、胆、胰疾病的诊治手段。ERCP后胰腺炎(PEP)是ERCP后最常见的并发症,文献报道发生率为1%~40%,在多数前瞻性随机研究中其发生率在4%~8%不等。有少数PEP患者可发展为重症急性胰腺炎(SAP),甚至可危及生命。近年来,许多学者致力于ERCP后胰腺炎的发病机制和药物预防研究,本文对这方面的进展作一综述。
引用
收藏
页码:456 / 459+462 +462
页数:5
相关论文
共 16 条
[1]
糖皮质激素预防ERCP术后胰腺炎的Meta分析 [J].
袁文明 ;
李静 ;
徐琳 ;
张小利 .
解放军医学杂志, 2007, (08) :805-807
[2]
Co-localization hypothesis: A mechanism for the intrapancreatic activation of digestive enzymes during the early phases of acute pancreatitis [J].
van Acker, Gijs J. D. ;
Perides, George ;
Steer, Michael L. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (13) :1985-1990
[3]
胰管支架置入术预防内镜逆行胰胆管造影术后胰腺炎的系统评价 [J].
潘涛 ;
王一平 ;
杨锦林 ;
田玲 ;
李耀东 .
中国循证医学杂志, 2004, (10) :693-699
[4]
Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: A 6-year survey and cost-effectiveness analysis [J].
Testoni, P. A. ;
Mariani, A. ;
Masci, E. ;
Curioni, S. .
DIGESTIVE AND LIVER DISEASE, 2006, 38 (08) :588-595
[5]
High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial [J].
Katsinelos, P ;
Kountouras, J ;
Chatzis, J ;
Christodoulou, K ;
Paroutoglou, G ;
Mimidis, K ;
Beltsis, A ;
Zavos, C .
GASTROINTESTINAL ENDOSCOPY, 2005, 61 (03) :407-415
[6]
The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis [J].
Schwartz, JJ ;
Lew, RJ ;
Ahmad, NA ;
Shah, JN ;
Ginsberg, GG ;
Kochman, ML ;
Brensinger, CM ;
Long, WB .
GASTROINTESTINAL ENDOSCOPY, 2004, 59 (02) :179-184
[7]
Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis:: a randomized double-blind trial [J].
Moretó, M ;
Zaballa, M ;
Casado, I ;
Merino, O ;
Rueda, M ;
Ramírez, K ;
Urcelay, R ;
Baranda, A .
GASTROINTESTINAL ENDOSCOPY, 2003, 57 (01) :1-7
[8]
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.[J].Bill Murray;Ross Carter;Clem Imrie;Susan Evans;Criostoir O’suilleabhain.Gastroenterology.2003, 7
[9]
Comparison of two dosing regimens of gabexate in the prophylaxis of Post-ERCP pancreatitis [J].
Masci, E ;
Cavallini, G ;
Mariani, A ;
Frulloni, L ;
Testoni, PA ;
Curioni, S ;
Tittobello, A ;
Uomo, G ;
Costamagna, G ;
Zarnbelli, S ;
Macarri, G ;
Innocenti, P ;
Dragonetti, C .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (10) :2182-2186
[10]
Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial [J].
Andriulli, A ;
Clemente, R ;
Solmi, L ;
Terruzzi, V ;
Suriani, R ;
Sigillito, A ;
Leandro, G ;
Leo, P ;
De Maio, G ;
Perri, F .
GASTROINTESTINAL ENDOSCOPY, 2002, 56 (04) :488-495